IDENTIFICATION OF ESTAZOLAM, ALPRAZOLAM AND TRIAZOLAM IN HUMAN URINE BY LC/MSⁿ

AIMTo investigate the fragmentation behavior of triazolobenzodiazepines and to develop a specific, sensitive and rapid LC/MSⁿ assay for simultaneous determination of estazolam, alprazolam and triazolam in human urine. METHODSAfter oral administration of a single 4 mg dose of the drugs to each of three healthy volunteers, urine samples were purified by solid-phase extraction, and then injected into an ODS column (150 mm×4.6 mm) with a mobile phase of methanol-water (8∶2) for LC/MSⁿ analysis. The structures of estazolam, alprazolam and triazolam in human urine were identified by direct comparison of the observed mass spectra and the chromatographic retention time with those of the reference substance. The mass spectrometer (Finnigan LCQ) was operated in positive mode and in two scan modes including SIM and full scan MS/MS mode. The obtained mass spectra was analyzed assisted with the software Mass Frontier 1.0 for their fragmentation pathways. RESULTSThe full scan MS/MS spectra of each compound gave characteristic fragment ions of ［M+H-N₂］⁺ and ［M+H-Cl］⁺. The detection limit was below 0.5 ng·mL^-1 for estazolam, alprazolam and triazolam in human urine. CONCLUSIONThe method is useful in forensic and clinical toxicology in which unequivocal identification of eatazolam, alprazolam and triazolam is desired.